Metraipolis › archive › dc_cd5d50327339

Trastuzumab deruxtecan in HER2-positive metastatic breast cancer with severe hepatic dysfunction: a case report and narrative literature review — Europe PMC PMID:42807143

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42807143
DOI
10.3389/fonc.2026.1753463
License (as archived)
solo-consultazione
Archived
2026-10-08T17:10:12.104Z
SHA-256 of the archived text
0d73ae089a266b0ea2a2890fc7c913b47356aa9764673a3bdb0010e199369709
Stable URL of this page
https://metraipolis.com/documento/dc_cd5d50327339

How to cite

Trastuzumab deruxtecan in HER2-positive metastatic breast cancer with severe hepatic dysfunction: a case report and narrative literature review — Europe PMC PMID:42807143 — Europe PMC (en), https://europepmc.org/article/MED/42807143 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_cd5d50327339 (Metraipolis archive dc_cd5d50327339, sha256 0d73ae089a266b0ea2a2890fc7c913b47356aa9764673a3bdb0010e199369709)
BibTeX
@misc{dccd5d50327339,
  title = {Trastuzumab deruxtecan in HER2-positive metastatic breast cancer with severe hepatic dysfunction: a case report and narrative literature review — Europe PMC PMID:42807143},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42807143},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_cd5d50327339; sha256 0d73ae089a266b0ea2a2890fc7c913b47356aa9764673a3bdb0010e199369709},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42807143. Agents can read the archived copy with the MCP tool read_document.